Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Orders All Injectables Inspected In Wake Of Three Deaths

This article was originally published in PharmAsia News

Executive Summary

China's State FDA ordered its local bureaus around the country to inspect all intravenous injectables by the end of the year to ensure none is contaminated. The agency took the action in the wake of at least three incidents in which people died after receiving an injection with an herb produced by Wandashan Pharmaceutical, later found to be contaminated with bacteria. SFDA bureaus were instructed to determine how an injection was produced, its ingredients, equipment used and other information through quality spot-checks and risk evaluation. (Click here for more

You may also be interested in...



Herbalife 'Just Getting Started' On Growth Following Flat 2019 At $4.9bn Net Sales

"We're a growth company, well-positioned in a global trend of nutrition that the world hasn't seen before," says co-president John Agwunobi. But the direct seller's record volume increase in 2019 didn’t translate to revenue growth as China, Mexico and Central and South America pulled down results.

US FDA Tech Modernization Plan’s Costs Uncertain

Agency officials determining needs using existing budgets before requesting more funds and will engage with tech investors for design advice.

ICER’s Biopharma Members: Why They Joined And What They Get

Biopharma’s funding support for the Institute for Clinical and Economic Review has been slightly above that of payers and providers for the past three to four years.

UsernamePublicRestriction

Register

SC067343

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel